Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib

SIMPLE SUMMARY: The drug sunitinib is used in metastatic renal cell carcinoma, but patients respond very differently to this drug. To better tailor sunitinib treatment to the individual patient, clinically useful markers are needed. We explored the DNA of patients with metastatic renal cell cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Diekstra, Meta H. M., Swen, Jesse J., van der Zanden, Loes F. M., Vermeulen, Sita H., Boven, Epie, Mathijssen, Ron H. J., Fukunaga, Koya, Mushiroda, Taisei, Hongo, Fumiya, Oosterwijk, Egbert, Cambon-Thomsen, Anne, Castellano, Daniel, Fritsch, Achim, Donas, Jesus Garcia, Rodriguez-Antona, Cristina, Ruijtenbeek, Rob, Radu, Marius T., Eisen, Tim, Junker, Kerstin, Roessler, Max, Jaehde, Ulrich, Miki, Tsuneharu, Böhringer, Stefan, Kubo, Michiaki, Kiemeney, Lambertus A. L. M., Guchelaar, Henk-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220885/
https://www.ncbi.nlm.nih.gov/pubmed/35740506
http://dx.doi.org/10.3390/cancers14122838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220885/
https://www.ncbi.nlm.nih.gov/pubmed/35740506
http://dx.doi.org/10.3390/cancers14122838

Ejemplares similares